Intervention Protocol

TNF-alpha inhibitors for psoriatic arthritis

  1. Dominik Golicki1,*,
  2. Tomasz Macioch1,
  3. Maciej Niewada2,
  4. Michal Jakubczyk1,
  5. Malgorzata Tlustochowicz3,
  6. Witold Owczarek4,
  7. Witold Tlustochowicz3

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 8 JUL 2009

DOI: 10.1002/14651858.CD007940


How to Cite

Golicki D, Macioch T, Niewada M, Jakubczyk M, Tlustochowicz M, Owczarek W, Tlustochowicz W. TNF-alpha inhibitors for psoriatic arthritis (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD007940. DOI: 10.1002/14651858.CD007940.

Author Information

  1. 1

    Medical University of Warsaw, Department of Pharmacoeconomics, Warsaw, Poland

  2. 2

    Medical University of Warsaw, Department of Clinical Pharmacology, Warsaw, Poland

  3. 3

    Military Institute of the Health Services, Department of Internal Diseases and Rheumatology, Warsaw, Poland

  4. 4

    Military Institute of the Health Services, Department of Dermatology, Warsaw, Poland

*Dominik Golicki, Department of Pharmacoeconomics, Medical University of Warsaw, Pawinskiego 3A, Warsaw, 02-106, Poland. dominik.golicki@wum.edu.pl. dominik.golicki@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 8 JUL 2009

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The aim of this review is to assess the efficacy and safety of the TNF-alpha inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab and onercept) in patients with PsA when compared with placebo or current standard treatment.

This review will address four core questions.

1. What is the clinical efficacy of TNF-alpha inhibitors for the treatment of PsA in terms of:

  • relieving symptoms?
  • improving health related quality of life?
  • delaying disease progression?

2. What are the risks (frequency and severity of adverse events) associated with use of TNF-alpha inhibitors in these patients?